• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Gray William Garrett sold $271,984 worth of shares (74,110 units at $3.67), decreasing direct ownership by 5% to 1,458,644 units (SEC Form 4)

    2/7/25 8:30:17 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CKPT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GRAY WILLIAM GARRETT

    (Last) (First) (Middle)
    95 SAWYER RD, SUITE 110

    (Street)
    WALTHAM MA 02453

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Checkpoint Therapeutics, Inc. [ CKPT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    COMMON STOCK 02/06/2025 S(1) 74,110 D $3.67(2) 1,458,644(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. In connection with the vesting of 187,200 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Gray's tax withholding obligations. Mr. Gray had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
    2. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.55 to $3.84. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
    3. Includes shares of restricted common stock, which vest over various time periods.
    /s/ Garrett Gray 02/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CKPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CKPT

    DatePrice TargetRatingAnalyst
    1/13/2025$9.00Buy
    D. Boral Capital
    7/14/2022$7.00Buy
    B. Riley Securities
    1/25/2022$17.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CKPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, President and Director Oliviero James F Iii sold $60,964 worth of shares (15,090 units at $4.04), decreasing direct ownership by 0.40% to 3,759,929 units (SEC Form 4)

      4 - Checkpoint Therapeutics, Inc. (0001651407) (Issuer)

      4/3/25 7:27:55 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Gray William Garrett sold $49,904 worth of shares (12,322 units at $4.05), decreasing direct ownership by 0.84% to 1,446,322 units (SEC Form 4)

      4 - Checkpoint Therapeutics, Inc. (0001651407) (Issuer)

      4/3/25 7:26:36 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Fortress Biotech, Inc. was granted 18,500 shares, increasing direct ownership by 0.30% to 6,222,249 units (SEC Form 4)

      4 - Checkpoint Therapeutics, Inc. (0001651407) (Issuer)

      2/27/25 4:25:08 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CKPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

      Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and adva

      3/31/25 4:05:13 PM ET
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

      WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates. Recent Corporate Updates: In March 2025, Checkpoint announced that it entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharma"), and a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving corporation of the transaction and a wholly owned subsidiary of Sun Pharma (the "Merger"). The total transaction value

      3/28/25 8:30:04 AM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Checkpoint Therapeutics

      Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /P

      3/9/25 10:06:00 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CKPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CKPT
    Leadership Updates

    Live Leadership Updates

    See more
    • D. Boral Capital initiated coverage on Checkpoint Therapeutics with a new price target

      D. Boral Capital initiated coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $9.00

      1/13/25 8:29:55 AM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities resumed coverage on Checkpoint Therapeutics with a new price target

      B. Riley Securities resumed coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $7.00

      7/14/22 9:44:00 AM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Checkpoint Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $26.00 from $17.00 previously

      1/25/22 9:58:19 AM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

      WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca Rare Disease, where he guides and executes the strategic direction of development products and programs within Alexion's nephrology franchise across all stages of development. Prior to joining Alexion, he served as Vice Presiden

      3/18/24 8:00:46 AM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CKPT
    Financials

    Live finance-specific insights

    See more
    • Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

      WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates. Recent Corporate Updates: In March 2025, Checkpoint announced that it entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharma"), and a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving corporation of the transaction and a wholly owned subsidiary of Sun Pharma (the "Merger"). The total transaction value

      3/28/25 8:30:04 AM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Checkpoint Therapeutics

      Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /P

      3/9/25 10:06:00 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

      Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

      8/14/23 4:01:50 PM ET
      $ATXI
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CKPT
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Checkpoint Therapeutics Inc.

      DEFM14A - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

      4/23/25 5:09:41 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Checkpoint Therapeutics Inc.

      PREM14A - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

      4/14/25 5:30:17 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Checkpoint Therapeutics Inc.

      10-K - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

      3/28/25 4:15:35 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CKPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Checkpoint Therapeutics Inc.

      SC 13G/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

      11/14/24 4:49:25 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Checkpoint Therapeutics Inc.

      SC 13D/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

      10/1/24 4:15:18 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Checkpoint Therapeutics Inc. (Amendment)

      SC 13D/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

      5/17/24 5:13:09 PM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care